These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Sun H; Meng W; Zhu J; Wang L Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):643-658. PubMed ID: 35307759 [TBL] [Abstract][Full Text] [Related]
25. A novel angiogenic effect of PCSK9- regulated genes. Zhan X; Jiang L; Wang L; Liu J; Kang S; Liu H; Lin L Gene; 2023 Feb; 852():147051. PubMed ID: 36427678 [TBL] [Abstract][Full Text] [Related]
26. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. Chorba JS; Galvan AM; Shokat KM J Biol Chem; 2018 Feb; 293(6):1875-1886. PubMed ID: 29259136 [TBL] [Abstract][Full Text] [Related]
27. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Cesaro A; Bianconi V; Gragnano F; Moscarella E; Fimiani F; Monda E; Scudiero O; Limongelli G; Pirro M; Calabrò P Biofactors; 2020 May; 46(3):367-380. PubMed ID: 31999032 [TBL] [Abstract][Full Text] [Related]
28. Hypercholesterolemia: The role of PCSK9. Melendez QM; Krishnaji ST; Wooten CJ; Lopez D Arch Biochem Biophys; 2017 Jul; 625-626():39-53. PubMed ID: 28587771 [TBL] [Abstract][Full Text] [Related]
29. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008 [TBL] [Abstract][Full Text] [Related]
30. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA. Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977 [TBL] [Abstract][Full Text] [Related]
31. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
33. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. Picard C; Poirier A; Bélanger S; Labonté A; Auld D; Poirier J; PLoS One; 2019; 14(8):e0220254. PubMed ID: 31437157 [TBL] [Abstract][Full Text] [Related]
34. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067 [TBL] [Abstract][Full Text] [Related]
35. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. Ly K; Essalmani R; Desjardins R; Seidah NG; Day R J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865 [TBL] [Abstract][Full Text] [Related]
36. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? Mannarino MR; Sahebkar A; Bianconi V; Serban MC; Banach M; Pirro M J Clin Lipidol; 2018; 12(5):1123-1132. PubMed ID: 30318062 [TBL] [Abstract][Full Text] [Related]
37. Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection. Muzammil K; Hooshiar MH; Varmazyar S; Omar TM; Karim MM; Aadi S; Kalavi S; Yasamineh S Microb Cell Fact; 2024 Mar; 23(1):90. PubMed ID: 38528584 [TBL] [Abstract][Full Text] [Related]
38. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Lagace TA Curr Opin Lipidol; 2014 Oct; 25(5):387-93. PubMed ID: 25110901 [TBL] [Abstract][Full Text] [Related]
39. Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Levstek T; Karun T; Rehberger Likozar A; Šebeštjen M; Trebušak Podkrajšek K Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980904 [TBL] [Abstract][Full Text] [Related]
40. Role of PCSK9 in lipid metabolism and atherosclerosis. Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]